首页> 外文会议>International Forum on Leading Edge Technologies on Crystallization Engineering and Pharmaceutics Development;Tianjin University;Tianjin Medical University >Drug Discovery Targeting PRC2 to Alter Epigenetics for Therapeutics of Triple Negative Breast Cancer

【24h】

Drug Discovery Targeting PRC2 to Alter Epigenetics for Therapeutics of Triple Negative Breast Cancer

机译：药物发现靶向PRC2以改变三重阴性乳腺癌治疗的表观遗传学

获取原文

页面导航

著录项
相似文献
相关主题

著录项

来源
《International Forum on Leading Edge Technologies on Crystallization Engineering and Pharmaceutics Development;Tianjin University;Tianjin Medical University》||7-8|共2页
会议地点
作者
Duxin Sun;
展开▼
作者单位

展开▼
会议组织
原文格式 PDF
正文语种
中图分类药学;
关键词
入库时间 2022-08-26 13:58:31

相似文献

外文文献
中文文献
专利

1. Targeting long non-coding RNA DANCR inhibits triple negative breast cancer progression Targeting long non-coding RNA DANCR inhibits triple negative breast cancer progression Targeting long non-coding RNA DANCR inhibits triple negative breast cancer progression [J] . Dongya Yuan, Yuejun Liu, Baosan Han, Biology Open . 2017,第9期

机译：靶向长非编码RNA DANCR抑制三阴性乳腺癌进展靶向长非编码RNA DANCR抑制三阴性乳腺癌进展靶向长非编码RNA DANCR抑制三阴性乳腺癌进展
2. Targeting long non-coding RNA DANCR inhibits triple negative breast cancer progression Targeting long non-coding RNA DANCR inhibits triple negative breast cancer progression Targeting long non-coding RNA DANCR inhibits triple negative breast cancer progression [J] . Dongya Yuan, Yuejun Liu, Baosan Han, Biology Open . 2017,第9期

机译：靶向长非编码RNA DANCR抑制三阴性乳腺癌进展靶向长非编码RNA DANCR抑制三阴性乳腺癌进展靶向长非编码RNA DANCR抑制三阴性乳腺癌进展
3. Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers [J] . Loo Ser Yue, Syn Nicholas L., Koh Angele Pei-Fern, Cell death discovery. . 2021,第1期

机译：表观遗传DERELAGESS将PPARγ转化为三重阴性和内分泌抗性乳腺癌的可药剂靶标
4. Leukocyte-based biomimetic nanoparticles as a targeted drug delivery vehicle for triple-negative breast cancer [C] . Manuela Sushnitha, Jonathan O. Martinez, Kelly A. Hartman, Society for Biomaterials annual meeting and exposition . 2018

机译：基于白细胞的仿生纳米颗粒作为三阴性乳腺癌的靶向药物载体
5. Identification of LRP8, CDCA7, and MLK4 as Novel Therapeutic Targets for Cancer Stem Cells in Triple-negative Breast Cancer [D] . Lin, Chang-Ching. 2018

机译：鉴定LRP8，CDCA7和MLK4作为三阴性乳腺癌中癌症干细胞的新疗法靶标
6. Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer [O] . Stephen Kalscheuer, Vidhi Khanna, Hyunjoon Kim, -1

机译：HSPG2（Perlecan）作为三阴性乳腺癌的治疗靶标的发现
7. LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer [O] . J. D. Obayemi, A. A. Salifu, S. C. Eluu, 2020

机译：LHRH-缀合的药物作为靶向治疗剂的特异性靶向和局部治疗三重阴性乳腺癌
8. PPAR Delta as a Therapeutic Target in Triple-Negative Breast Cancers. [R] . Qi, C. 2012

机译：ppaR Delta作为三阴性乳腺癌的治疗靶点。

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号